AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
AdvanCell has successfully completed an oversubscribed US$112 million Series C financing round, co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis. The clinical-stage radiopharmaceutical company, founded in June 2019, has grown to include 60 team members and a 40,000-square-foot manufacturing facility.
The funding will support expansion of manufacturing capacity and accelerate clinical development of radionuclide therapies. The company is currently conducting the TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer, testing a Pb-212-based radionuclide treatment.
Following the financing, Jamil M. Beg, Christopher Gagliardi, and Bali Muralidhar have joined AdvanCell's Board of Directors. The company's focus on Targeted Alpha Therapies and scalable isotope supply aims to advance cancer treatment, particularly in prostate cancer and gastroenteropancreatic neuroendocrine tumours.
AdvanCell ha completato con successo un finanziamento di Serie C di 112 milioni di dollari americani, che ha suscitato un grande interesse, co-guidato da SV Health Investors, Sanofi Ventures, Abingworth e SymBiosis. L'azienda, attiva nel campo dei radiofarmaci e fondata nel giugno 2019, è cresciuta fino a comprendere 60 membri nel team e una struttura di produzione di 40.000 piedi quadrati.
I fondi saranno utilizzati per espandere la capacità produttiva e accelerare lo sviluppo clinico delle terapie a base di radionuclidi. Attualmente, l'azienda sta conducendo la sperimentazione clinica TheraPb Fase I/II di escalation della dose di ADVC001 per il carcinoma prostatico metastatico, testando un trattamento radionuclide a base di Pb-212.
Dopo il finanziamento, Jamil M. Beg, Christopher Gagliardi e Bali Muralidhar si sono uniti al Consiglio di Amministrazione di AdvanCell. L'azienda si concentra sulle Terapie Alpha Mirate e su un approvvigionamento scalabile di isotopi, con l'obiettivo di progredire nel trattamento del cancro, in particolare nel carcinoma prostatico e nei tumori neuroendocrini gastroenteropancreatici.
AdvanCell ha completado con éxito una ronda de financiación de Serie C de 112 millones de dólares estadounidenses, que fue sobreelementada, co-liderada por SV Health Investors, Sanofi Ventures, Abingworth y SymBiosis. La empresa de radiofármacos en etapa clínica, fundada en junio de 2019, ha crecido hasta incluir 60 miembros en su equipo y una instalación de fabricación de 40,000 pies cuadrados.
La financiación apoyará la expansión de la capacidad de fabricación y acelerará el desarrollo clínico de terapias con radionúclidos. Actualmente, la empresa está llevando a cabo el ensayo clínico TheraPb Fase I/II de escalado de dosis de ADVC001 para el cáncer de próstata metastásico, probando un tratamiento de radionúclido basado en Pb-212.
Tras la financiación, Jamil M. Beg, Christopher Gagliardi y Bali Muralidhar se han unido a la Junta Directiva de AdvanCell. El enfoque de la empresa en las Terapias Alfa Dirigidas y el suministro escalable de isótopos tiene como objetivo avanzar en el tratamiento del cáncer, especialmente en el cáncer de próstata y los tumores neuroendocrinos gastroenteropancreáticos.
AdvanCell이 초과 청약된1억 1200만 달러 규모의 C 시리즈 자금 조달을 성공적으로 완료했습니다. 이 자금 조달은 SV Health Investors, Sanofi Ventures, Abingworth 및 SymBiosis가 공동 주도했습니다. 2019년 6월에 설립된 임상 단계의 방사선 제약 회사는 60명의 팀원과 4만 평방피트의 제조 시설을 갖추고 성장했습니다.
이번 자금은 제조 능력 확장과 방사성 핵종 치료제의 임상 개발 가속화를 지원할 것입니다. 현재 회사는 전이성 전립선암을 위한 ADVC001의 TheraPb 1상/2상 용량 조절 임상 시험을 진행 중이며, Pb-212 기반 방사성 핵종 치료를 시험하고 있습니다.
자금 조달 후, Jamil M. Beg, Christopher Gagliardi 및 Bali Muralidhar가 AdvanCell의 이사회에 합류했습니다. 전립선암 및 위장내분비 신경내분비 종양 치료를 촉진하기 위한 목표로 타겟 알파 치료 및 확장 가능한 동위원소 공급에 집중하고 있습니다.
AdvanCell a réalisé avec succès un financement de Série C de 112 millions de dollars américains, sursouscrit, co-dirigé par SV Health Investors, Sanofi Ventures, Abingworth et SymBiosis. Fondée en juin 2019, cette entreprise de radio-pharmaceutiques en phase clinique compte maintenant 60 membres dans son équipe et une usine de fabrication de 40 000 pieds carrés.
Ce financement soutiendra l'extension de la capacité de production et accélérera le développement clinique des thérapies au radionucléide. Actuellement, l'entreprise mène un essai clinique de montée de dose TheraPb Phase I/II d'ADVC001 pour le cancer de la prostate métastatique, testant un traitement au radionucléide basé sur le Pb-212.
Suite à ce financement, Jamil M. Beg, Christopher Gagliardi et Bali Muralidhar ont rejoint le conseil d'administration d'AdvanCell. L'accent mis par l'entreprise sur les thérapies alpha ciblées et l'approvisionnement en isotopes évolutif vise à faire progresser le traitement du cancer, en particulier dans le cas du cancer de la prostate et des tumeurs neuroendocrines gastro-entéro-pancréatiques.
AdvanCell hat erfolgreich eine Überzeichnung der Serie-C-Finanzierungsrunde in Höhe von 112 Millionen US-Dollar abgeschlossen, die von SV Health Investors, Sanofi Ventures, Abingworth und SymBiosis gemeinsam geleitet wurde. Das im Juni 2019 gegründete Unternehmen für radiopharmazeutische Arzneimittel im klinischen Stadium ist auf 60 Teammitglieder und eine Produktionsanlage mit einer Fläche von 40.000 Quadratfuß angewachsen.
Die Finanzierung wird die Erweiterung der Produktionskapazität unterstützen und die klinische Entwicklung von Radionuklidtherapien beschleunigen. Das Unternehmen führt derzeit die klinische Studie TheraPb Phase I/II zur Dosiserhöhung von ADVC001 bei metastasiertem Prostatakrebs durch und testet eine Pb-212-basierte Radionuklidbehandlung.
Nach der Finanzierung sind Jamil M. Beg, Christopher Gagliardi und Bali Muralidhar dem Vorstand von AdvanCell beigetreten. Der Fokus des Unternehmens auf gezielte Alpha-Therapien und skalierbare Isotopenversorgung zielt darauf ab, die Krebsbehandlung voranzutreiben, insbesondere bei Prostatakrebs und gastroenteropancreatischen neuroendokrinen Tumoren.
- Secured substantial US$112M in oversubscribed Series C funding
- Expanded to 60 team members and 40,000-square-foot manufacturing facility since 2019
- Ongoing Phase I/II clinical trial for prostate cancer treatment
- Established collaborations with major pharmaceutical companies
- None.
Insights
The US$112 million Series C round for AdvanCell marks a pivotal moment in the rapidly evolving radiopharmaceutical sector. The oversubscription indicates strong institutional confidence in both the technology and market opportunity, particularly noteworthy given the current challenging biotech funding environment.
The investor syndicate is especially telling - the participation of Sanofi Ventures and other strategic investors suggests potential future partnership or acquisition opportunities. These investors typically seek companies with clear paths to commercialization and strategic fit with major pharmaceutical portfolios.
AdvanCell's Pb-212 platform technology offers distinct advantages in the targeted alpha therapy space. Lead-212's half-life and energy profile potentially enable superior tumor penetration and reduced off-target effects compared to existing radionuclide therapies. The company's 40,000-square-foot manufacturing facility addresses a critical industry bottleneck - the reliable production and supply of medical isotopes.
The ongoing Phase I/II trial for metastatic prostate cancer represents a US$7+ billion market opportunity. Current standard-of-care treatments like Novartis's Pluvicto and Bayer's Xofigo have validated the radiopharmaceutical approach in prostate cancer, but there remains significant room for improved efficacy.
The US$112 million raise provides an estimated 24-30 month runway, sufficient to reach key clinical milestones. The company's rapid growth from founding to 60 employees and clinical-stage assets in under 5 years demonstrates strong execution capabilities. The addition of experienced board members from leading healthcare investors should help guide their next phase of growth.
The therapeutic potential of AdvanCell's Pb-212 platform represents a significant advancement in targeted alpha therapy. The physical properties of Pb-212, including its 10.6-hour half-life and high-energy alpha particle emission, create an optimal therapeutic window that could potentially improve both efficacy and safety compared to current radiopharmaceuticals.
The company's focus on PSMA-targeted therapy for prostate cancer is strategically sound. Current radionuclide treatments have demonstrated survival benefits but face limitations in terms of supply chain complexity and treatment resistance. AdvanCell's manufacturing infrastructure addresses these challenges while potentially offering improved tumor penetration and more precise targeting.
The ongoing Phase I/II dose escalation trial is particularly noteworthy as it approaches the highest dose cohort. This suggests encouraging safety data from lower doses, a critical milestone for radiopharmaceutical development. The trial design, focusing on metastatic prostate cancer, targets a patient population with significant unmet medical need despite recent therapeutic advances.
AdvanCell's 40,000-square-foot manufacturing facility represents a significant competitive advantage. The ability to reliably produce and supply medical isotopes in-house could accelerate development timelines and reduce costs, addressing a major industry bottleneck that has the broader adoption of radiopharmaceutical therapies.
Since its founding in June 2019, AdvanCell has grown from a belief in the potential of Targeted Alpha Therapy into a global organisation with 60 passionate team members, a 40,000-square-foot manufacturing facility, world-class pre-clinical infrastructure, a potentially best-in-class drug for prostate cancer that is in trials, and a deep and developing pipeline of assets.
This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity, accelerate the clinical development of its pipeline of radionuclide therapies, and advance its mission of delivering life-changing treatments to cancer patients worldwide.
AdvanCell is currently enrolling patients for the highest dose cohort of its multi-center TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer, a potentially best-in-class Targeted Alpha Therapy. The trial aims to demonstrate the safety and efficacy of Pb-212-based radionuclide treatment.
As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell Board of Directors. They bring extensive industry expertise to support the company’s growth and join existing directors Bill Ferris AC, Anthony Aiudi, Kevin Cameron, and Andrew Adamovich.
Jamil M. Beg, Partner at SV Health Investors, commented:
“We are delighted to support AdvanCell’s growth and play a role in its remarkable journey through leading this oversubscribed Series C. We have looked long and deep at the field of radionuclide therapies and are confident that AdvanCell stands out with a first-in-class Pb-212-PSMA program and a best-in-class manufacturing platform. The company’s exceptional team, technologies, robust infrastructure, collaborations with some of the world’s largest pharma companies and ability to consistently execute, position it to truly change outcomes for patients. We are excited to help AdvanCell realize its potential in transforming cancer care globally.”
AdvanCell was founded on the belief that Targeted Alpha Therapies could change the course of cancer treatment and that the scalable supply of isotopes would enable the development of multiple practice-changing drugs. Radionuclide therapies for prostate cancer and gastroenteropancreatic neuroendocrine tumours have transformed patient care. Pb-212 Targeted Alpha Therapy has the potential to further advance this progress by leveraging the radiobiological and physical attributes of Pb-212 to make life-changing treatments for patients.
“This successful Series C round demonstrates strong confidence in our vision and capabilities,” said Andrew Adamovich, CEO of AdvanCell. “We are grateful for the continued support from our existing investors, particularly the long-term support from Morningside and are excited to welcome new partners who share our commitment to transforming cancer care. With this funding, AdvanCell is well-positioned to scale our manufacturing operations and progress our cutting-edge therapies towards commercialization.”
The Series C funding represents a significant step in AdvanCell’s journey to become a global leader in radionuclide-based cancer therapeutics.
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
About SV Health Investors
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV funds invest across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, medical devices, healthcare growth and healthcare technology. With approximately
About Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences that align with Sanofi’s mission to bring life-changing treatments to patients worldwide. For more information, please visit www.sanofiventures.com.
About Abingworth
Abingworth is a leading transatlantic life sciences investment firm and part of the global investment firm Carlyle (NASDAQ: CG). Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 185 life science companies, leading to 50+ M&As and more than 75 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in
About SymBiosis Capital Management
SymBiosis is an investment firm focused on advancing biotherapeutics innovations for serious and life-threatening diseases. The firm invests in groundbreaking medicines across disease areas, financing stages, and geography, with a focus on programs in, or about to enter, human trials. SymBiosis currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments. For more information, please visit www.symbiosis.vc or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203887459/en/
For media inquiries, please contact:
Andrew Adamovich
CEO
Email: contact@advancell.com.au
Phone: +612 8000 4199
Source: AdvanCell
FAQ
How much did AdvanCell raise in their Series C funding round?
What is the current status of AdvanCell's ADVC001 clinical trial?
How will AdvanCell use the Series C funding?
What is AdvanCell's main therapeutic focus?
How has AdvanCell grown since its founding in 2019?
